Dashboard
Manage Tickers

ERAS Erasca, Inc.

Nasdaq erasca.com


$ 2.57 $ -0.11 (-4.15 %)    

Thursday, 13-Nov-2025 18:41:37 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 2.54
$ 2.65
$ 2.55 x 35
$ 2.68 x 1,178
-- - --
$ 1.01 - $ 3.30
1,301,224
na
720.63M
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-24-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-26-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

erasca-q3-eps-011-inline
Erasca Q3 EPS $(0.11), Inline
11/12/2025 21:04:03

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged...

erasca-announces-the-us-patent-and-trademark-office-has-issued-patent-no-12458647-for-its-pan-ras-molecular-glue-eras-0015-and-related-compounds
Erasca Announces The U.S. Patent And Trade...
11/06/2025 13:17:43

Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm...

stifel-initiates-coverage-on-erasca-with-buy-rating-announces-price-target-of-4
Stifel Initiates Coverage On Erasca with B...
10/16/2025 13:43:31

Stifel analyst Laura Prendergast initiates coverage on Erasca (NASDAQ:ERAS) with a Buy rating and announces Price Target of $4.

fidus-investment-rocket-companies-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Fidus Investment, Rocket Companies And Oth...
10/02/2025 12:45:54

why-concorde-international-group-shares-are-trading-higher-by-55-here-are-20-stocks-moving-premarket
Why Concorde International Group Shares Ar...
10/02/2025 09:48:36

this-accenture-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday
This Accenture Analyst Is No Longer Bullis...
09/03/2025 17:38:07

b-of-a-securities-downgrades-erasca-to-underperform-lowers-price-target-to-1
B of A Securities Downgrades Erasca to Und...
09/03/2025 12:12:18

B of A Securities analyst Alec Stranahan downgrades Erasca (NASDAQ:ERAS) from Buy to Underperform and lowers the price targe...

morgan-stanley-downgrades-erasca-to-equal-weight-lowers-price-target-to-2
Morgan Stanley Downgrades Erasca to Equal-...
08/18/2025 11:50:40

Morgan Stanley analyst Jeffrey Hung downgrades Erasca (NASDAQ:ERAS) from Overweight to Equal-Weight and lowers the price tar...

erasca-files-for-mixed-shelf-of-up-to-500m-sale-agreement-prospectus-covering-offering-of-up-200m-common-stock-that-may-be-issued-under-sale-agreement
Erasca Files For Mixed Shelf Of Up To $500...
08/12/2025 21:01:12

-SEC Filing

erasca-q2-eps-012-misses-011-estimate
Erasca Q2 EPS $(0.12) Misses $(0.11) Estimate
08/12/2025 20:16:02

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9...

erasca-secures-fda-clearance-for-first-in-class-pan-kras-inhibitor-eras-4001
Erasca Secures FDA Clearance For First-In-...
06/02/2025 12:29:57

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guid...

erasca-q1-eps-011-beats-012-estimate
Erasca Q1 EPS $(0.11) Beats $(0.12) Estimate
05/13/2025 20:18:16

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.3...

hc-wainwright--co-reiterates-buy-on-erasca-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Eras...
04/30/2025 10:42:19

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $6 price target.

erasca-presents-new-preclinical-data-for-profiles-of-ras-targeting-franchise-at-2025-aacr-annual-meeting
Erasca Presents New Preclinical Data For P...
04/29/2025 20:09:51

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapyFirst-in-class examples of dire...

wolverine-world-wide-pacira-biosciences-and-other-big-stocks-moving-higher-on-monday
Wolverine World Wide, Pacira BioSciences A...
04/21/2025 14:36:15

raymond-james-initiates-coverage-on-erasca-with-outperform-rating-announces-price-target-of-5
Raymond James Initiates Coverage On Erasca...
03/26/2025 12:12:30

Raymond James analyst Laura Prendergast initiates coverage on Erasca (NASDAQ:ERAS) with a Outperform rating and announces Pr...

goldman-sachs-maintains-buy-on-erasca-lowers-price-target-to-3
Goldman Sachs Maintains Buy on Erasca, Low...
03/21/2025 14:05:19

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $3.5 to $3.

hc-wainwright--co-reiterates-buy-on-erasca-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Eras...
03/21/2025 12:19:01

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $6 price target.

erasca-q4-2024-gaap-eps-011-beats-012-estimate
Erasca Q4 2024 GAAP EPS $(0.11) Beats $(0....
03/20/2025 20:06:47

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.3...

morgan-stanley-assumes-erasca-at-overweight-maintains-price-target-of-4
Morgan Stanley Assumes Erasca at Overweigh...
03/07/2025 17:27:00

Morgan Stanley analyst Jeffrey Hung assumes Erasca (NASDAQ:ERAS) with a Overweight rating and maintains Price Target of $4.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION